Characterization of tumor specific CD8+ T cell responses in patients with recurrent/metastatic HPV16-positive head and neck cancer receiving HB-200 monotherapy as second or later line treatment in a phase 1 study

Authors

AL Ho
Rom Leidner, ProvidenceFollow
See full list of authors in comments

Document Type

Abstract

Publication Date

11-1-2023

Keywords

oregon; chiles

Clinical Institute

Cancer

Department

Oncology

Comments

Ho AL, Pearson AT, Fu S, Posner MR, Adkins D, Nabell L, Niu J, Richardson DL, Leidner RS, Chung K, Laux D, Nieva J, Wong S, Rojas K, Rosenberg AJ, Phan M, Kaufmann T, Plescia C, Qing X, Iacobucci C, Tchakov I, Katchar K, Orlinger K, Schlienger K, Pfister DG. SITC Annual Meeting; November 1-5; San Diego, CA. 2023;11(Suppl 1): 679

Recommended Citation

Ho, AL; Leidner, Rom; and See full list of authors in comments, "Characterization of tumor specific CD8+ T cell responses in patients with recurrent/metastatic HPV16-positive head and neck cancer receiving HB-200 monotherapy as second or later line treatment in a phase 1 study" (2023). Articles, Abstracts, and Reports. 8347.
https://digitalcommons.providence.org/publications/8347